Slide 1: ViroGates A/S Company Presentation
1 ViroGates A/S Company Presentation May 2022
Slide 2: Forward-looking statements
2 Forward-looking statements Certain information set forth and given in this presentation contains “forward-looking information”, including “future oriented financial information” and “financial outlook”, under applicable securities laws (collectively referred to herein as forward-looking statements
Slide 3: ViroGates is an international medical technology company
3 ViroGates is an international medical technology company developing and marketing blood test products that improve patient outcomes Founded in 2001 Headquarter in Birkerød, Denmark 14 Initial public We improve patient outcomes employees offering in by suPARcharging triage for clinicians 2018
Slide 4: Healthcare systems are increasingly overburdened, emergency departments overcrowded
4 Healthcare systems are increasingly overburdened – and especially emergency departments are overcrowded THE TRENDS THE DATA Ageing population requiring long-term care 3% THE PROBLEM annual increase in European healthcare Increase in number of expenditures per capita diseases (NCD, age-related, Hea
Slide 5: We measure suPAR through blood tests
5 We measure suPAR through blood tests – an inflammatory biomarker that predicts negative patient outcomes suPAR (soluble urokinase Plasminogen Activator Receptor) suPAR is a naturally occurring protein in human blood suPAR reflects the immune system’s activation level suPAR predicts negative patien
Slide 6: suPAR used for emergency department triaging and guiding anakinra
6 suPAR is used for emergency department triaging and guiding anakinra treatment in COVID-19 patients 1 Patients referred by GPs, arriving by ambulances or walking in Emergency <4 ng/ml >6 ng/ml department SUPPORTS SUPPORTS DISCHARGE HOSPITALIZATION Low risk of negative High risk of outcome negative
Slide 7: We suPARcharge triage at the emergency department
7 We suPARcharge triage at the emergency department revealing more low-risk patients and slightly more high-risk patients Emergency department Mortality 9 patients (0.5%) Triage 5% 57% 39% without suPAR Up to ~22% reduction Mortality 6 patients (0.3%) in hospital admissions* Triage 9% 39% 52% with s
Slide 8: suPAR guiding anakinra treatment in COVID-19 department
8 suPAR is used for emergency department triaging and guiding anakinra treatment in COVID-19 patients 2 Patients requiring supplemental oxygen COVID-19 <6 ng/ml ≥6 ng/ml department STANDARD OF CARE ANAKINRA TREATMENT No expected benefit + STANDARD OF CARE from anakinra Expected benefit from treatmen
Slide 9: EMA has recommended suPAR-guided anakinra treatment in COVID-19
9 The European Medicines Agency has recommended suPAR-guided anakinra treatment in COVID-19 – data has been published in Nat Med 64% improved overall clinical outcome for COVID-19 patients • Significant prevention of death • Significant prevention of progression to severe respiratory failure • Signi
Slide 10: Using suPAR in clinical routine improves outcomes, reduces costs
10 Using suPAR in clinical routine improves patient outcomes, reduces healthcare costs and empowers clinical staff 1 Value propositions 2 Emergency department COVID-19 department 34% 64% more patients in the improvement in overall low risk category1 Improving Reducing clinical outcome4 patient healt
Slide 11: suPAR has the highest prognostic value compared to other biomarkers
11 suPAR has the highest prognostic value compared to complementary biomarkers and risk scoring systems Prognostic Consistently highest prognostic value for negative Complementary patient outcomes (e.g. mortality) biomarkers/systems Non-specific CRP Works across all types of potentially lethal disea
Slide 12: ViroGates sells recurring revenue products with gross margins above 75%
12 ViroGates sells recurring revenue products to healthcare customers in Europe with an average price of 15 EUR/test and gross margins above 75% suPARnostic® Products TurbiLatex Validated on Automated clinical use ~90% (Turbidimetric) recurring revenue Quick ELISA 10-20 EUR Triage per test 75-90% Ne
Slide 13: Addressable market size in Europe and North America
13 The addressable market size in Europe is ~340 EURm across the ED and COVID-19 – North America addressable market is ~280 EURm Addressable market sizes in Europe and North America EURm, 2022 North America Europe ~230 EURm ~280 EURm ~50 EURm ~60 EURm Emergency COVID-19 Emergency COVID-19 Department
Slide 14: Strategic focus on Acute Care in Europe through direct sales and distributors
14 ViroGates’ current strategic focus is on Acute Care in Europe through direct sales representatives and distributors (indirect sales) Direct sales Indirect sales Research use only
Slide 15: New fingerprick product launch expected in H1 2022: suPARnostic POC+
15 We still expect to launch a new fingerprick product in the first half of 2022 – the suPARnostic® POC+ +3 billion EUR annual market opportunity in Europe General • Health screens and Practitioners regular visits at the GP offices Prototype Small point-of-care device +1 billion EUR annual market op
Slide 16: Experienced management team and board
16 ViroGates has an experienced management team and board Management Team Non-Executive Board Jakob Knudsen, CEO, LL.M & MBA Dr. Lars Kongsbak (Chairman) • +15 years operational experience in life science • +25 years operational experience in • CEO ViroGates A/S since 2011, CCO and CFO Egalet Inc. l
Slide 17: Interim Report, Q1 2022
Interim Report, QI] 2022 May 2022 ViroGates
Slide 18: Revenue increased by 54% compared to Q1 2021
18 Revenue increased by 54% compared to Q1, 2021, driven by more customers, primarily within COVID-19 Financial results in Q1, 2022 (Q1, 2021 results in brackets) TDKK +54% • Revenue increased by 54% to TDKK 3,197 (TDKK 2,076) Revenue 2,076 3,197 • Operating expenses decreased by -6% to TDKK -5,819
Slide 19: Strong commercial traction with doubling routine hospital customers
19 ViroGates has strong commercial traction with doubling routine hospital customers in the latest quarter and strong shift to clinical sales Clinical routine hospital customers Sales by product # # Northern & Western Europe Other Quick Triage Southern Europe ELISA TurbiLatex Eastern Europe +120% 33
Slide 20: What should investors look out for in 2022?
20 What should investors look out for in 2022? COVID-19 New markets and suPARnostic® developments customers POC+ Future developments in the Potential future Expected launch of the COVID-19 pandemic and announcements of new suPARnostic® POC+ in the first potential announcements markets, clinical rout
Slide 21: Thank you for your attention!
21 Thank you for your attention! Jakob Knudsen +45 2226 1355 jk@virogates.com Mark Christian Hvidberg da Silva +45 6163 5600 mds@virogates.com